Skip to main content
. 2015 Oct 15;192(8):934–942. doi: 10.1164/rccm.201503-0543OC

Figure 4.

Figure 4.

Roflumilast therapy does not affect systemic proline-glycine-proline (PGP). There were no statistical differences in plasma (A) acetyl-proline-glycine-proline (AcPGP) and (B) PGP, suggesting the antiinflammatory effect is most pronounced in the lung. Open bars represent the placebo group (n = 16), and solid bars represent the roflumilast group (n = 11). Values expressed as mean ± SEM. NS = not significant.